Revolutionizing

Immunotherapy

Harnessing the power of the immune system to combat disease.

Advancing global health with pioneering immunotherapy solutions

BioVaxys stands at the forefront of biotechnological innovation, with a focus on developing advanced antigen presentation methods and treatments in oncology, infectious disease, antigen desensitization, allergy, autoimmune diseases, and other immune dysfunctions

BioVaxys now combines Haptenix©, its groundbreaking antigen haptenization technology and the DPX™ delivery platform to address some of the most pressing medical challenges of our time.

Haptenization Science

Immunological Synergy

T-Cell Antigen Discovery Program

AI in Immunotherapy

DPX™ Delivery Platform

Acquired from IMV Inc., the DPX™ platform is a cutting-edge lipid-based delivery system. It's designed for encapsulating a diverse array of bioactive molecules, leading to enhanced and sustained immune responses.

Learn More

Haptenix© - Ovarian Cancer Vaccine

The company is distinguished by the application of it’s Haptenix© technology platform.  Haptenization,  a pioneering technique developed from the work of Nobel laureate Dr. Karl Landsteiner, is a process that uses chemicals called ‘haptens’ to train the immune system to recognize and aggressively target tumor or viral proteins, thus enhancing  T cell response against both tumor and viral antigens. This is critical, as T-cells target and destroy viral or cancerous cells.  The Haptenix© platform technology is the foundation of BVX-0918, the Company’s Phase I vaccine candidate for Stage III/Stage IV ovarian cancer.

Learn More

Partner collaboration and open innovation.

We collaborate with leading institutions and universities and hold exclusive patents in haptenized vaccine technologies and T cell-mediated immune response diagnostics.

BioVaxys is a publicly-listed company.

5LB
BIOV
BVAXF
5LB
BIOV
BVAXF
5LB
BIOV
BVAXF
5LB
BIOV
BVAXF

Contact Us

Lorem ipsum dolor sit amet, consectetur adipiscing elit suspendisse.

Email
support@genix.com
Phone
Office. +22 234-54-8910
Office
New York, 398 11th St, United States